Over 2 years ago, the Food and Drug Administration (FDA) held hearings on the use of social media for pharmaceutical advertising. WOMMA representatives provided testimony during those hearings. Comments concerning issues presented by those hearings were provided by many industry groups, including WOMMA.
Anticipation has been great, with the expectation that clarity would be provided for pharmaceutical companies desiring to use social media platforms as part of the educational and promotional activities. After years of waiting by the pharmaceutical industry, the FDA quietly released its “Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices” in the Federal Register. Unfortunately, the agency declined to provide detailed instructions and rules.
Instead, the draft guidance addresses how manufacturers and distributors of prescription human and animal drug products and medical devices can respond to unsolicited requests for information about unapproved or uncleared indications or conditions of use related to FDA-approved or -cleared products.
The guidance divides off-label requests for information into two categories: public and nonpublic. If a consumer makes a public request – on a Web site or in a third-party discussion platform – the company should limit its response to providing its contact information so that individuals can follow up independently with the firm to obtain specific information about the off-label use of the product through a nonpublic, one-on-one communication. Yet, when a consumer asks a question in a nonpublic setting, via e-mail or hotline, for example, companies should respond in a private, one-on-one communication.
The information provided in response should be “truthful, non-misleading, accurate, balanced, and non-promotional,” the agency said, tailored to answer only the specific question asked. The answer should include complete copies of scientific reprints, technical literature, or other medical information, not just summary documents, and should also include representative publications that reach contrary or different conclusions regarding the use at issue. In addition, the answer should include a copy of the FDA-required labeling, a complete list of references for the information included, and prominent statements that the FDA has not approved the product as safe for the use addressed as well as the indications currently approved and all relevant safety information.
Companies should maintain a record of their conversation with the consumer.
The FDA said that the guidance “is the first of multiple draft guidances the agency plans to publish that address questions and issues related to emerging electronic media,” acknowledging that it has received a petition from drug manufacturers, held public hearings, and received over 70 public comments on the topic. Formal Comments on the current draft guidance will be accepted until March 29, 2012.







WOMMA Asks FTC for Clearer Disclosure in Online Advertising « Ad Network Magazine 11:22 am on August 12, 2011 Permalink
[...] “Emerging technologies provide significant consumer benefits, and new media marketing and promotions have been embraced by brands and consumers alike, said Anthony DiResta, WOMMA General Counsel, in a press release. [...]